Immuron (IMRN) FDA Approvals

Immuron logo
$0.90 +0.05 (+5.86%)
Closing price 11/20/2026 03:49 PM Eastern
Extended Trading
$0.83 -0.07 (-7.54%)
As of 11/20/2026 05:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immuron's Drugs in the FDA Approval Process

This section highlights FDA-related milestones and regulatory updates for drugs developed by Immuron (IMRN). Over the past two years, Immuron has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Travelan and IMM-529. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Select a button below to view the list of FDA events for that drug.

Travelan FDA Regulatory Timeline and Events

Travelan is a drug developed by Immuron for the following indication: To prevent infectious diarrhea caused by enterotoxigenic Escherichia coli (ETEC). This drug is approved by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

IMM-529 FDA Regulatory Timeline and Events

IMM-529 is a drug developed by Immuron for the following indication: Oral polyclonal antibody, targeting toxin B in the human gut and neutralises main virulence factors of Clostridium infection. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Immuron FDA Events - Frequently Asked Questions

Yes, Immuron (IMRN) has received FDA approval for Travelan. This page tracks recent and historical FDA regulatory events related to Immuron's drug portfolio.

In the past two years, Immuron (IMRN) has reported FDA regulatory activity for the following drugs: Travelan and IMM-529.

The most recent FDA-related event for Immuron occurred on October 13, 2026, involving Travelan. The update was categorized as "Data," with the company reporting: "Immuron Limited announced that data from its Phase 2 clinical trial of once-daily oral Travelan® has been published in the Nature Journal, Scientific Reports."

Current therapies from Immuron in review with the FDA target conditions such as:

  • To prevent infectious diarrhea caused by enterotoxigenic Escherichia coli (ETEC). - Travelan
  • Oral polyclonal antibody, targeting toxin B in the human gut and neutralises main virulence factors of Clostridium infection - IMM-529
  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

FDA progress for NASDAQ:IMRN last updated on 10/13/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data.
From Our Partners